Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Longest Journey: An Interview with Hira Thapliyal

Executive Summary

Born in a remote village in India, Hira Thapliyal played a critical role in the creation of many early technologies used in interventional cardiology, including DVI's atherectomy device and CVIS' intravascular ultrasound. However, he's perhaps best known as one of the founders of ArthroCare. In this interview adapted from the Stanford BioDesign Program's Innovators Workbench series, Thapliyal looks back on his early career.

You may also be interested in...



ArthroCare's Next Act

Ten years ago, ArthroCare was just one of dozens of small medical device start-ups to have gone public in the IPO boom of 1995 and 1996. But while most of ArthroCare's classmates in what has come to be known as the Class of '96 have disappeared, ArthroCare is a fast-growing, self-sustaining public company. Its core technology-a radio-frequency-based ablation tool called Coblation--results in faster healing times, with a fraction of the pain of other modalities that remove tissue. It has thus been picked up by a number of physican specialities including ENT surgeons and orthopedic surgeons, and for a large number of applications. ArthroCare now faces a host of new challenges, most notably, how to continue to capitalize and build on its proprietary plasma-mediated technology and, in the process, how to sustain that growth and the share price rewards that come with it.

ArthroCare's Magic Wand

ArthroCare believes its new approach to tissue removal represents a quantum leap forward in arthroscopy and can be used in other clinical markets. But dogged by a perception that it didn't know what it wanted to do--it talked about new opportunities before it could act on them--ArthroCare now has to convince investors that it can deliver on its promises.

Novartis And The Medicines Company: Five Things To Worry About

The $9.7bn acquisition hinges on the small interfering RNA inclisiran, but an ongoing cardiovascular outcomes trial, manufacturing hurdles, and reimbursement challenges provide subjects for concern.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV003348

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel